Study of joint health in people taking tirzepatide
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Hormones & metabolism, Skin clinical trials.
This is an observational study tracking how tirzepatide affects joint and heart health over one year. Researchers will collect images, blood samples, and body composition measurements to understand whether tirzepatide helps with joint inflammation and related conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and currently taking tirzepatide prescribed by your doctor for diabetes, weight management, or related metabolic conditions
- You have or have had a documented joint problem, such as joint pain with inflammation, psoriatic arthritis, knee osteoarthritis, or spine/joint inflammation confirmed by a doctor
- Your medical records include documentation of your joint condition before you started tirzepatide
- You can attend follow-up visits over 52 weeks and undergo MRI scans of both knees and a heart CT scan without contraindications
- You plan to continue tirzepatide for at least 52 weeks, and you have not started or changed arthritis biologic medications in the past 12 weeks
- You have not had joint injections (steroid or hyaluronic acid) in the past 6 weeks and have not had major joint surgery in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study tests adding tirzepatide (a once-weekly injection for weight and diabetes) to your current treatment with ixekizumab for psoriatic arthritis. It may help with both joint symptoms and weight.
This trial examines how well tirzepatide works for weight loss in people with obesity, and how it's actually used in daily life. It may be an option if you haven't tried other obesity treatments and don't have diabetes.
This study tests whether tirzepatide, a medication for weight management, affects muscle health in women with obesity. It may help if you are looking for a treatment that preserves muscle while losing weight.
This study tests whether combining a newer weight-loss medication (tirzepatide) with a structured exercise program helps improve muscle strength and function in people who are overweight or obese. Researchers will measure changes in muscle quality and physical fitness over time.
This study tests if the drug tirzepatide can improve muscle and blood vessel health in older adults with obesity. You may be eligible if you are 50 or older, have a BMI between 30 and 40, and do not have diabetes.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.